Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

18. Februar 2022

Dechow T, Aldaoud A, Behlendorf T, Knauf W, Eschenburg H, Groschek M, Hansen R, Söling U, Grebhardt S, Siebenbach HU, Vannier C, Potthoff K, 2022.

European Journal of Haematology, Volume 108, Issue 2, p. 133-144, 2022.
https://doi.org/10.1111/ejh.13719